Eagle's Eye View: Your Weekly CV Update From ACC.org
By American College of Cardiology
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by American College of Cardiology
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 26
Reviews: 0
Episodes: 100
Description
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
| Episode | Date |
|---|---|
|
Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure
|
May 27, 2026 |
|
HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS)
|
May 20, 2026 |
|
Rhythm Control & Tricuspid Valve Regurgitation; Benefits of Blood Pressure Control on Cardiovascular Disease; Switching DOAC Therapy in AFIB Patients with Stroke; Pulsed Field Ablation & Persistent AFib
|
May 13, 2026 |
|
Pulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG
|
May 06, 2026 |
|
Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans
|
Apr 29, 2026 |
|
Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease
|
Apr 22, 2026 |
|
Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
|
Apr 15, 2026 |
|
Top Takeaways from ACC.26
|
Apr 08, 2026 |
|
New ACC/AHA Dyslipidemia Guidelines Released
|
Mar 18, 2026 |
|
Beta-Blocker vs. Calcium-Channel Blocker in HCM
|
Mar 11, 2026 |
|
Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
|
Mar 04, 2026 |
|
Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
|
Feb 24, 2026 |
|
ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
|
Feb 04, 2026 |
|
Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes
|
Jan 28, 2026 |
|
The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT
|
Jan 21, 2026 |
|
Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes
|
Jan 14, 2026 |
|
Eagle's Eye View: Top 2025 ACC Content
|
Jan 07, 2026 |
|
Weight Reversal Post Tirzepatide Withdrawal
|
Dec 17, 2025 |
|
The PREVENT Equations & Cardiovascular Risk, the CREST-2 Trials on Carotid Disease , Physician Burnout, Food Labeling & CV Health
|
Dec 10, 2025 |
|
Improving The Culture and Climate Surrounding Cardiology
|
Dec 03, 2025 |
|
Gastrointestinal Bleeding After LAAO, Lifestyle Modification & Metabolic Syndrome, Beta-Blockers & the Treatment of Preserved LVEF
|
Nov 26, 2025 |
|
Eagle's Eye View: Highlights from the 2025 AHA Scientific Sessions
|
Nov 12, 2025 |
|
Highlights From 2025 TCT Conference
|
Nov 05, 2025 |
|
Aspirin, Anticoagulants, & Chronic Coronary Disease; Perioperative Blood Pressure Management; High-Dose Flu Vaccines & Hospitalizations
|
Oct 29, 2025 |
|
Heart Disease Mortality in California; Pregnant Women and Cardiometabolic Comorbidities; CABG and New-Onset AFib
|
Oct 22, 2025 |
|
Evidence and Innovations Targeting Inflammation Post-AMI
|
Oct 15, 2025 |
|
A Look at ACC's Scientific Statement on Inflammation and CVD
|
Oct 08, 2025 |
|
Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
|
Oct 01, 2025 |
|
Nonatherothrombotic Myocardial Infarction and SCAD in Younger Patients; the Benefit of Intensive Blood Pressure Control; Clopidogrel vs. Aspirin for Prevention of CV Events
|
Sep 24, 2025 |
|
Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
|
Sep 17, 2025 |
|
Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
|
Sep 10, 2025 |
|
Self-Service Blood Pressure Kiosks; the FLAVOUR Trial & Intermediate Coronary Stenosis; CPAP & Cardiovascular Outcomes
|
Aug 27, 2025 |
|
New ACC/AHA Blood Pressure Guidelines; Right Angle Branch Blocks & Pacemakers; Gender-Affirming Care & Cardiac Repolarization
|
Aug 20, 2025 |
|
Compression Socks & Vasovagal Syncope; Management of Pericarditis; Early Cardiac Rehab for ADHF.
|
Aug 14, 2025 |
|
BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement
|
Jul 30, 2025 |
|
BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement
|
Jul 30, 2025 |
|
The PREVENT Model & Risk Prediction; Carbohydrate Quality & Improved LV Structure; Radial Access for PCI & Lower Complication Rates
|
Jul 23, 2025 |
|
AV after TTVR; Deep Learning in Automating Cardiac IMG; Survival Benefits Post-2018 Heart Transplantation Policy Change
|
Jul 16, 2025 |
|
Ischemic Preconditioning & Noncardiac Surgery; The Microaxial Flow Pump in STEMI-CS; DOACs After Strokes
|
Jul 09, 2025 |
|
Frailty Status and Mortality Risk in PCI; Delays in Treatment in STEMI; Arterial Events with Genetic-based Vascular Disease
|
Jun 25, 2025 |
|
LAAO and the Watchman FLX; HF Care in Private Equity Hospitals; Long-term Outcomes in TR and Mitral Valve-in-Valve Replacement
|
Jun 18, 2025 |
|
Marijuana Use & Endothelial Function; CV & Bleeding With Aspirin v. Clopidogrel; Mental Health for Survivors of SCA and ICD Shock
|
Jun 11, 2025 |
|
Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
|
May 28, 2025 |
|
Colchicine vs. Placebo in Reducing CV Events; DOACs vs. Warfarin After TAVR; CSP vs. BiVP and Echo Response
|
May 21, 2025 |
|
ORBITA-2 & PCI; Blood Pressure Control & Increasing Medication Prescriptions; Rapid Initiation & Titration in GRMT for Patients with HFrEF
|
May 14, 2025 |
|
Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib
|
Apr 30, 2025 |
|
Weight Management in Pregnancy and CVD Risk; Impact of Statins Plus Ezetimibe Post-MI; PARTNER-3 Study 5-year Results
|
Apr 23, 2025 |
|
Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs)
|
Apr 16, 2025 |
|
Key Takeaways from ACC.25 Major Trials and Presentations
|
Apr 02, 2025 |
|
Cardiogenic Shock Guidance; Mortality after Mitral Repair & TAVR; Direct-to-Physician Marketing Affects GDMT
|
Mar 26, 2025 |
|
Smoking & CVD Risk; Sleep, Diabetes, & Women with Gestational Diabetes; Post-TAVR Imaging
|
Mar 19, 2025 |
|
Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
|
Mar 12, 2025 |
|
Identifying Myocardial Infarction after PCI; Myocardial Fibrosis & Severe Aortic Valve Stenosis; Anticoagulation & Cancer Diagnoses
|
Mar 05, 2025 |
|
SGLT2 Inhibitors & Aortic Valve Stenosis; Early vs. Later Ablation for Afib; Sports Participation by Athletes with Cardiac Abnormalities
|
Feb 26, 2025 |
|
Arrhythmia Recurrence & Rhythm Control after Catheter Ablation for AFib; Transthyretin Amyloid Cardiomyopathy & Tafamidis; Sodium Restriction & BP
|
Feb 19, 2025 |
|
Blood Pressure & Postpartum; Beta Blockers & Takotsubo Syndrome; Secondary Prevention Worldwide
|
Feb 12, 2025 |
|
Cardiac Rehab & Heart Failure, CV Care & Cancer Survivors, Bioprosthetic AVR vs Mechanical AVR in Younger Patients
|
Feb 05, 2025 |
|
Cost-effectiveness of Polypills, Obesity and FH, Adverse Pregnancy Outcomes and Long-term HF Risk
|
Jan 29, 2025 |
|
Left Atrial Appendage Occlusion & Stroke, Hypertrophic Cardiomyopathy in Children, Anticoagulation & COVID-19
|
Jan 22, 2025 |
|
Top Trials, Journal Scans, and Takeaways of 2024
|
Dec 23, 2024 |
|
What Cardiologists Should Know About Congenital Heart Disease, Cardiac Arrest and Death in Athletes, Arrhythmia After Stroke
|
Dec 18, 2024 |
|
Management of Myocarditis; Sex Differences in PCI vs. CABG; RVOT Dysfunction in Repaired TOF
|
Dec 11, 2024 |
|
Compression Tights in Patients With POTS, Platelet Function and Genetic Testing in PCI, Aspirin in Stent Patients Undergoing Noncardiac Surgery
|
Dec 04, 2024 |
|
Prevalence of U.S. Overweight and Obesity, Consensus on CPR, Bleeding Risk Using NSAIDs With Anticoagulants
|
Nov 27, 2024 |
|
Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart
|
Nov 21, 2024 |
|
Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart
|
Nov 21, 2024 |
|
Exercise Training in HCM; Management of Kawasaki Disease; Race, Social Determinants of Health, Polygenic Risk for CHD
|
Nov 20, 2024 |
|
Transseptal Mitral Valve-in-Valve Procedure, Complete vs. Culprit-Only Revascularization in Older Patients, Hypertensive Pregnancy and MI Risk
|
Nov 13, 2024 |
|
TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure
|
Nov 06, 2024 |
|
Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment
|
Nov 05, 2024 |
|
Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses
|
Oct 30, 2024 |
|
Real-time AI to Influence Clinical Decisions and Practice Towards Evidence-based Care: RAPIDxAI Trial
|
Oct 29, 2024 |
|
Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI
|
Oct 23, 2024 |
|
Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
|
Oct 16, 2024 |
|
CV Events After COVID Vaccine, Septal Reduction in Obstructive HCM, Acute Pulmonary Embolism Guideline Comparison
|
Oct 09, 2024 |
|
Hospital Survival After AAA Repair, Myocardial Fibrosis and Aortic Stenosis, MRA Use in HF
|
Oct 02, 2024 |
|
Risk Stratification in Nonischemic Dilated Cardiomyopathy, 2024 Guideline for Perioperative CV Management for Noncardiac Surgery, Lipoprotein(a) and Cardiovascular Disease
|
Sep 25, 2024 |
|
Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome
|
Sep 18, 2024 |
|
Eight Practice-Changing Trials Featured at ESC Congress 2024
|
Sep 12, 2024 |
|
Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients
|
Sep 11, 2024 |
|
SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants
|
Sep 04, 2024 |
|
Social Determinants of Health in Cardiology, Aortopathy in Children, Cardiac CT Following Left Atrial Appendage Occlusion
|
Aug 28, 2024 |
|
Genetics and Risk in Aortic Disease, Plant vs. Animal Fat in Cardiovascular Outcomes, Management of Cardiac Sarcoidosis
|
Aug 21, 2024 |
|
Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease
|
Aug 14, 2024 |
|
Pulmonary Hypertension and HF, Obesity in Adolescents, Noncardiac Surgery After TAVR
|
Aug 07, 2024 |
|
Fenestrated-Branched Endovascular Aortic Repair, Mortality and PCI, Lp(a) and Calcific Aortic Stenosis Progression
|
Jul 31, 2024 |
|
Diuretics and HF, Implantable Cardioverter-Defibrillators and the Tricuspid Valve and Right Ventricle, Neurohormonal Blockade and HF
|
Jul 24, 2024 |
|
Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss
|
Jul 17, 2024 |
|
Iron Repletion and Heart Failure, Ventricular Septal Defect and Acute Myocardial Infarction, Hemodynamic Assessment for HF
|
Jul 10, 2024 |
|
Early Rhythm Control, Low-Dose Aspirin and Prevention, Autoimmune Diseases and Atherosclerosis
|
Jul 02, 2024 |
|
In-office and At-Home Blood Pressure Measurement, Artificial Intelligence and Cardiovascular Care, Inflammatory Risk
|
Jun 26, 2024 |
|
Severe Aortic Stenosis, Titration and Acute Heart Failure, Pacemakers After TAVR
|
Jun 18, 2024 |
|
Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes
|
Jun 12, 2024 |
|
Anticoagulation in Post-Operative AFib, Non-ST-Elevation Acute Coronary Syndromes, Arrhythmia-Induced Cardiomyopathy
|
Jun 05, 2024 |
|
Aortic Valve Calcification and Aortic Stenosis, Microvascular Resistance Reserve After PCI, Microvascular Injury Patterns
|
May 29, 2024 |
|
Transcatheter-Based Intervention and Tetralogy of Fallot, Small Left Ventricle and Atrial Fibrillation (Afib), Aspirin Free Treatment Post-PCI
|
May 22, 2024 |
|
Guideline for the Management of Lower Extremity Peripheral Artery Disease (PAD), Decongestion Strategies for Heart Failure, Lipoproteins and Triglycerides in Cardiovascular Prevention
|
May 15, 2024 |
|
Eagle's Eye View: The New AHA/ACC Hypertrophic Cardiomyopathy Guideline, Smoking Cessation, Embolic Stroke
|
May 08, 2024 |
|
Eagle's Eye View: Pulsed Field Ablation and Pulmonary Vein Isolation, Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives, TAVR or SAVR and Severe Aortic Stenosis
|
May 01, 2024 |
|
Eagle's Eye View: Cardiac Sarcoidosis, Ischemic Stroke in Women with Atrial Fibrillation, TAVR and Native Aortic Regurgitation
|
Apr 24, 2024 |